Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 4 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Angiomax — BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
Application NDA208374 (NDA)
Cubicin — DAPTOMYCIN
Application NDA209949 (NDA)
Cysteine Hydrochloride — NOURESS
Application NDA212535 (NDA)
Angiomax — ANGIOMAX RTU
Application NDA211215 (NDA)
Cysteine Hydrochloride — ELCYS
Application NDA210660 (NDA)
Cytoxan — CYCLOPHOSPHAMIDE
Application NDA212501 (NDA)
Cytoxan — CYCLOPHOSPHAMIDE
Application NDA210735 (NDA)
Mycamine — MICAFUNGIN
Application NDA212125 (NDA)
Cubicin — DAPTOMYCIN
Application NDA210282 (NDA)
Mycamine — MICAFUNGIN
Application NDA212156 (NDA)
Ancef — CEFAZOLIN IN DEXTROSE
Application NDA207131 (NDA)
Ancef — CEFAZOLIN SODIUM
Application NDA216109 (NDA)
Cubicin — DAPZURA RT
Application NDA213645 (NDA)
Mycamine — MICAFUNGIN IN SODIUM CHLORIDE 0.9%
Application NDA216142 (NDA)
Cytoxan — CYCLOPHOSPHAMIDE
Application NDA217150 (NDA)
Cytoxan — CYCLOPHOSPHAMIDE
Application NDA217651 (NDA)
Cytoxan — FRINDOVYX
Application NDA210852 (NDA)
Ancef — CEFAZOLIN SODIUM
Application NDA211413 (NDA)
Cubicin — DAPTOMYCIN
Application NDA217415 (NDA)
Cubicin — DAPTOMYCIN
Application NDA217630 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)